Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galecto, Inc. stock logo
GLTO
Galecto
$3.65
+4.3%
$3.24
$2.01
$15.14
$4.83M1.3585,774 shs5,599 shs
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
$0.76
+4.1%
$2.02
$0.62
$12.00
$3.39M-0.08726,784 shs11,470 shs
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
$0.19
-21.0%
$0.24
$0.15
$0.47
$903K1.3418,280 shs22,141 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.58
-1.1%
$3.20
$1.75
$9.00
$5.87M1.33796,429 shs44,468 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galecto, Inc. stock logo
GLTO
Galecto
+0.45%+4.88%+7.41%+46.75%-74.98%
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
-7.43%-8.75%-74.56%-69.58%-80.12%
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
-1.75%+44.03%-2.00%-16.00%-34.67%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-1.63%+13.13%+17.53%+57.39%+805.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Galecto, Inc. stock logo
GLTO
Galecto
3.5115 of 5 stars
3.55.00.00.02.21.71.3
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
1.6395 of 5 stars
0.05.00.00.01.13.30.6
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
0.2006 of 5 stars
0.05.00.00.00.00.00.0
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.7306 of 5 stars
0.05.00.00.02.80.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Galecto, Inc. stock logo
GLTO
Galecto
3.00
Buy$10.00173.97% Upside
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
0.00
N/AN/AN/A
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
2.00
HoldN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Galecto, Inc. stock logo
GLTO
Galecto
N/AN/AN/AN/A$10.99 per shareN/A
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
$536.36K6.33N/AN/A$1.59 per share0.48
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
N/AN/AN/AN/A($18.37) per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.41N/AN/A$2.73 per share1.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Galecto, Inc. stock logo
GLTO
Galecto
-$21.44M-$15.53N/AN/AN/AN/A-98.27%-84.29%8/11/2025 (Estimated)
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
-$5.02M-$4.08N/AN/A-988.83%-224.08%-172.88%N/A
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
-$25.26M-$71.13N/AN/AN/AN/A-302.61%N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$3.10N/AN/AN/A-24.23%-58.73%-21.05%8/6/2025 (Estimated)

Latest PBLA, SNOA, GLTO, and LIPO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
5/14/2025Q1 2025
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
N/A-$0.64N/A-$0.64N/A$0.13 million
5/8/2025Q1 2025
Galecto, Inc. stock logo
GLTO
Galecto
N/A-$1.92N/A-$1.92N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Galecto, Inc. stock logo
GLTO
Galecto
N/AN/AN/AN/AN/A
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
N/AN/AN/AN/AN/A
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Galecto, Inc. stock logo
GLTO
Galecto
N/A
9.62
9.62
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
N/A
6.21
6.21
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
N/A
0.26
0.26
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.09
2.38

Institutional Ownership

CompanyInstitutional Ownership
Galecto, Inc. stock logo
GLTO
Galecto
14.20%
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
74.31%
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
4.37%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
Galecto, Inc. stock logo
GLTO
Galecto
10.80%
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
32.11%
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
0.01%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
3.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Galecto, Inc. stock logo
GLTO
Galecto
401.32 million1.18 millionOptionable
Lipella Pharmaceuticals Inc. stock logo
LIPO
Lipella Pharmaceuticals
44.47 million3.03 millionNot Optionable
Panbela Therapeutics, Inc. stock logo
PBLA
Panbela Therapeutics
64.86 million4.86 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.58 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market
Sonoma Pharmaceuticals, Inc. (O8Z.F)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Galecto stock logo

Galecto NASDAQ:GLTO

$3.65 +0.15 (+4.29%)
Closing price 04:00 PM Eastern
Extended Trading
$3.70 +0.05 (+1.37%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Lipella Pharmaceuticals stock logo

Lipella Pharmaceuticals NASDAQ:LIPO

$0.76 +0.03 (+4.10%)
As of 03:54 PM Eastern

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Panbela Therapeutics stock logo

Panbela Therapeutics NASDAQ:PBLA

$0.19 -0.05 (-20.96%)
As of 03:21 PM Eastern

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.58 -0.04 (-1.10%)
Closing price 04:00 PM Eastern
Extended Trading
$3.50 -0.08 (-2.09%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.